Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo

To the Editor: Vitiligo is an advancing autoimmune skin disorder distinguished by the presence of skin patches with depigmentation, 1 Ezzedine K. Eleftheriadou V. Whitton M. van Geel N. Vitiligo. Lancet. 2015; 386: 74-84 Abstract Full Text Full Text PDF PubMed Scopus (545) Google Scholar first- and second-line treatments often fail to provide effective results for many cases. Upadacitinib, an oral selective JAK1 inhibitor, has demonstrated potential therapeutic effects for vitiligo. 2 Montilla A.M. Gómez-García F. Gómez-Arias P.J. et al. Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther. 2019; 9: 655-683 Crossref PubMed Scopus (53) Google Scholar In this study, upadacitinib was evaluated for its effectiveness and safety in treating recalcitrant vitiligo patients.